Robert Reich / RobertReich.OrgMar 11, 2018
The recently sentenced businessman's story is tragic and pathetic, but he isn't really different from other figures who dominate American life today. Dig deeper ( 3 Min. Read )
Staff / TruthdigFeb 5, 2016
Embattled Turing Pharmaceuticals CEO Martin Shkreli apparently did not show up for his hearing Thursday before the House Oversight Committee with a mind to shift public opinion in his favor or convince attendant legislators that he held anything resembling respect for the proceedings. Dig deeper ( 2 Min. Read )
Alexander Reed Kelly / TruthdigNov 26, 2015
The disreputable pharmaceutical boss has reneged on an agreement to lower the price of a medication he raised from $13.50 to $750 per pill. Dig deeper ( 1 Min. Read )
Join our newsletterStay up to date with the latest from Truthdig. Join the Truthdig Newsletter for our latest publications.
BLANKSep 27, 2015
The drug company CEO who announced a 5,000 percent increase in the price of a lifesaving drug was forced to back down after Twitter users, the industry and others exploded in outrage. We have three words for these sometimes rude commenters: Good for you. Dig deeper ( 3 Min. Read )
Staff / TruthdigSep 23, 2015
In case you hadn't heard, last month, Turing Pharmaceuticals CEO and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 per pill. Now he has a big public relations problem and a self-created health care crisis on his hands. Dig deeper ( 1 Min. Read )
Join our newsletterDon't miss out on the latest investigations, art critiques, provocative insights and original reporting from a progressive perspective — delivered straight to your inbox.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, please login or create a user profile.
Now you can personalize your Truthdig experience. To bookmark your favorite articles and follow your favorite authors, upgrade to supporter.